JPH10508003A - 腫瘍および感染部位に指向させるためのビオチン化合物 - Google Patents
腫瘍および感染部位に指向させるためのビオチン化合物Info
- Publication number
- JPH10508003A JPH10508003A JP8501283A JP50128396A JPH10508003A JP H10508003 A JPH10508003 A JP H10508003A JP 8501283 A JP8501283 A JP 8501283A JP 50128396 A JP50128396 A JP 50128396A JP H10508003 A JPH10508003 A JP H10508003A
- Authority
- JP
- Japan
- Prior art keywords
- group
- biotin
- composition
- reagent
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の構造式を有するビオチンアミドアナログ化合物。 式中、 n= 2〜10; R1〜R5=H、アシル基、アルキル基、アルキレン基、アルケニレン基、アルキニ レン基、アルケニル基、またはアルキニル基、 R6=H、アシル基、アルキル基、アルキレン基、アルケニレン基、アルキニレン 基、アルケニル基、もしくはアルキニル基;または結合した治療用試薬もしくは 診断用試薬;かつ X= C=O、S=O、またはC=NH。 2.ビオチンアミドアナログが、[3aS-(3aα,4β,6aα)]-ヘキサヒドロ-2-オ キソ-1H-チエノ[3,4d]イミダゾール4-(N-3-(1-フルオロプロピル))ペンタ ンアミド([3aS-(3aα,4β,6aα)]-hexahydro-2-oxo-1H-thieno[3,4d]imi dazole 4-(N-3-(1-fluoropropyl))pentanamido)である、請求の範囲1の組 成物。 3.R6が、結合した治療用試薬、または治療用試薬に結合したビオチンの組成物 である、請求の範囲1の組成物。 4.請求の範囲3の組成物と薬剤学的に許容される担体とを含む、薬学的組成物。 5.治療用試薬が、薬物、毒物、放射性核種、ホルモン拮抗薬、重金属錯体、オ リゴヌクレオチド、化学療法用ヌクレオチド、ペプチド、非特異的(非抗体)タ ンパク質、ホウ素含有化合物およびエネジン(enediynes)からなる群より選択 されたものである、請求の範囲4の薬学的組成物。 6.有効量の請求の範囲5の組成物を被検者に投与することを含む、被検者におけ る腫瘍または感染部位の発生または生長を治療または抑制する方法。 7.感染が細菌感染である、請求の範囲6の方法。 8.細菌感染が大腸菌感染である、請求の範囲7の方法。 9.R6が結合したイメージング試薬である、請求の範囲1の組成物。 10.イメージング試薬が、In-111、Tc-99m、I-123、I-125 F-18、Ga-67、Ga-68 、常磁性原子、およびコントラスト試薬からなる群より選択されたものである、 請求の範囲9の組成物。 11.請求の範囲9の組成物を被検者に投与し、適当な手段を用いて該組成物を検 出またはモニターすることを含む、被検者における腫瘍または感染部位をイメー ジングする方法。 12.以下の構造式を有するビオチン化合物。 式中、 n= 2〜10 R1〜R5= H、アシル基、アルキル基、アルキレン基、アルケニレン基、アルキニ レン基、アルケニル基またはアルキニル基、 R6= H、アシル基、アルキル基、アルキレン基、アルケニレン基、アルキニレン 基、アルケニル基もしくはアルキニル基;または結合した治療用試薬もしくは診 断用試薬、 X= C=O、S=O、またはCNH、かつ 2、3、もしくは4位= O、S、またはN。 13.R6が結合した治療用試薬である、請求の範囲12の組成物。 14.請求の範囲13の組成物と薬剤学的に許容される担体とを含む、薬学的組成物 。 15.治療用試薬が、薬物、毒物、放射性核種、ホルモン拮抗薬、重金属錯体、オ リゴヌクレオチド、化学療法のヌクレオチド、ペプチド、非特異的(非抗体)タ ンパク質、ホウ素含有化合物、およびエネジン(enediyne)からなる群より選択 されたものである、請求の範囲14の薬学的組成物。 16.有効量の請求の範囲15の組成物を被検者に投与することを含む、被検者にお ける腫瘍または感染部位の発生または生長を治療または抑制する方法。 17.感染が、細菌、ウイルス、真菌、または原生動物の感染からなる群より選択 されたものである、請求の範囲16の方法。 18.R6が結合したイメージング試薬である、請求の範囲12の組成物。 19.イメージング試薬が、In-111、Tc-99m、I-123、I-125 F-18、Ga-67、Ga-68 、常磁性原子、およびコントラスト試薬からなる群より選択されたものである、 請求の範囲9の組成物。 20.請求の範囲17の組成物を被検者に投与し、適当な手段を用いてその組成物を 検出またはモニターすることを含む、被検者における腫瘍または感染部位をイメ ージングするための方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25426094A | 1994-06-06 | 1994-06-06 | |
US08/254,260 | 1994-06-06 | ||
US26551694A | 1994-06-24 | 1994-06-24 | |
US08/265,516 | 1994-06-24 | ||
PCT/US1995/007184 WO1995033491A1 (en) | 1994-06-06 | 1995-06-05 | Biotin compounds for targetting tumors and sites of infection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007183924A Division JP2007302686A (ja) | 1994-06-06 | 2007-07-13 | 腫瘍および感染部位に指向させるためのビオチン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10508003A true JPH10508003A (ja) | 1998-08-04 |
JP4013996B2 JP4013996B2 (ja) | 2007-11-28 |
Family
ID=26943939
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50128396A Expired - Fee Related JP4013996B2 (ja) | 1994-06-06 | 1995-06-05 | 腫瘍および感染部位に指向させるためのビオチン化合物 |
JP2007183924A Withdrawn JP2007302686A (ja) | 1994-06-06 | 2007-07-13 | 腫瘍および感染部位に指向させるためのビオチン化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007183924A Withdrawn JP2007302686A (ja) | 1994-06-06 | 2007-07-13 | 腫瘍および感染部位に指向させるためのビオチン化合物 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0769966B1 (ja) |
JP (2) | JP4013996B2 (ja) |
AT (1) | ATE268186T1 (ja) |
AU (1) | AU700864B2 (ja) |
CA (1) | CA2192384A1 (ja) |
DE (1) | DE69533105T2 (ja) |
HK (1) | HK1014670A1 (ja) |
WO (1) | WO1995033491A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20030269A1 (it) * | 2003-02-14 | 2004-08-15 | Advance Holdings Ltd | Sale di cetilpiridino di un agente antiinfiammatorio |
CN110183504B (zh) * | 2019-06-13 | 2023-07-07 | 湖南大学 | 一种具有肿瘤靶向性的吉西他滨前体药物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5258126A (en) * | 1989-09-12 | 1993-11-02 | Pall Corporation | Method for obtaining platelets |
DE4011601A1 (de) * | 1990-04-10 | 1991-10-17 | Boehringer Mannheim Gmbh | Hapten-biotin-konjugate und ihre verwendung |
US5326778A (en) * | 1992-03-03 | 1994-07-05 | Research Corporation Technologies, Inc. | Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy |
EP1138334A3 (en) * | 1992-06-09 | 2002-04-03 | Neorx Corporation | Pretargeting methods and compounds |
US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
-
1995
- 1995-06-05 DE DE69533105T patent/DE69533105T2/de not_active Expired - Fee Related
- 1995-06-05 AT AT95922233T patent/ATE268186T1/de not_active IP Right Cessation
- 1995-06-05 JP JP50128396A patent/JP4013996B2/ja not_active Expired - Fee Related
- 1995-06-05 WO PCT/US1995/007184 patent/WO1995033491A1/en active IP Right Grant
- 1995-06-05 EP EP95922233A patent/EP0769966B1/en not_active Expired - Lifetime
- 1995-06-05 CA CA002192384A patent/CA2192384A1/en not_active Abandoned
- 1995-06-05 AU AU26991/95A patent/AU700864B2/en not_active Ceased
-
1998
- 1998-12-28 HK HK98116076A patent/HK1014670A1/xx not_active IP Right Cessation
-
2007
- 2007-07-13 JP JP2007183924A patent/JP2007302686A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2192384A1 (en) | 1995-12-14 |
DE69533105D1 (de) | 2004-07-08 |
JP4013996B2 (ja) | 2007-11-28 |
AU700864B2 (en) | 1999-01-14 |
HK1014670A1 (en) | 1999-09-30 |
DE69533105T2 (de) | 2005-06-09 |
JP2007302686A (ja) | 2007-11-22 |
WO1995033491A1 (en) | 1995-12-14 |
ATE268186T1 (de) | 2004-06-15 |
AU2699195A (en) | 1996-01-04 |
EP0769966B1 (en) | 2004-06-02 |
EP0769966A1 (en) | 1997-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5716594A (en) | Biotin compounds for targetting tumors and sites of infection | |
Kung et al. | In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans | |
Qingnuan et al. | Preparation of 99mTc-C60 (OH) x and its biodistribution studies | |
Shoup et al. | Synthesis of fluorine-18-labeled biotin derivatives: biodistribution and infection localization | |
JP2002519440A5 (ja) | ||
WO1992019210A2 (en) | Serotinin reuptake inhibitors for s.p.e.c.t imaging | |
CN110496233B (zh) | 一种spect显像剂及其标记前体及其制备方法、组合物和用途 | |
EP1099693A1 (en) | Radiolabelled peptide compounds | |
Foulon et al. | Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy | |
Lundkvist et al. | Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter | |
JP4013996B2 (ja) | 腫瘍および感染部位に指向させるためのビオチン化合物 | |
CA1339130C (en) | Markers of tissue hypoxia | |
BRPI0616441A2 (pt) | derivados de diamino da biotina e seus conjugados com agentes quelantes macrocìclicos | |
AU2002237517B2 (en) | Biotin-derivatives and their conjugates with chelating agents | |
AU743255B2 (en) | Biotin compounds for targeting tumors and sites of infection | |
AU2002237517A1 (en) | Biotin-derivatives and their conjugates with chelating agents | |
EP1154798B1 (en) | Molecules for the treatment and diagnosis of tumors | |
Foulon et al. | Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: Biotinyl-3-[211At] astatoanilide | |
Avcıbaşı et al. | In vivo biodistribution of 131 I labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal models | |
Mizojiri et al. | Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C] S-1108 in rats and dogs | |
US7230115B1 (en) | Preparation of compounds useful for the detection of hypoxia | |
Lakshmi et al. | (R)-N-Methyl-3-(3-125I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters | |
US12023390B2 (en) | Isomerically pure 18F-labelled tetrahydrofolates | |
JP3522754B2 (ja) | 多価フェノール化合物類 | |
McPherson et al. | Stereoselective synthesis, in vitro, and initial in vivo evaluation of 1-methylpiperidin-4-yl α-hydroxy-α-(1-iodo-1-propen-3-yl)-α-phenylacetate (IPIP): a novel radioiodinated molecular probe with high affinity for the muscarinic receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060428 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060424 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060718 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061017 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070713 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070802 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070810 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070904 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100921 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |